ZTS
Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other related products.
Zoetis Inc. (ZTS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | B (3.2) | D+ (1.8) | B+ (3.7) | B- (3.1) | F (0.3) | C (2.4) |
| 2026-11-09 | B (3.2) | D+ (1.8) | B+ (3.7) | C+ (2.7) | F (0.3) | C (2.4) |
| 2026-11-07 | B (3.2) | D+ (1.8) | B+ (3.7) | C (2.2) | F (0.3) | C (2.2) |
| 2026-11-05 | B (3.2) | C- (1.9) | B+ (3.7) | C (2.2) | F (0.4) | C (2.3) |
| 2026-11-04 | B (3.2) | D+ (1.8) | B+ (3.7) | C- (2.1) | F (0.1) | C (2.2) |